Three Strikes, But Not Out Yet, Lilly’s Donanemab Approval Delayed Again

Accelerated Approval Snub Was More Than A Year Ago

Brain Xray
Donanemab safety and efficacy both are likely topics for the Adcomm • Source: Shutterstock

More from New Products

More from Scrip